



CIBERDEM/MSD LA DIABETES A DEBATE 2019: Diabetes in the Knowledge frontier

9 de Noviembre de 2019. 11:00h - 16:00h. Círculo de Bellas Artes. Madrid.

Agenda:

- Link between diabetes and cancer.
- Pharmacological novelties in the SGLT2i class
- Glycaemic variability, does it matter?: how do we measure it and its clinical implication for type 2 diabetes.



Síganos en [@msd_es](https://twitter.com/msd_es)

10:30h -11:15h

COFFEE & WELCOME

Dr. Eduard Montanya

CIBERDEM Scientific Director, Endocrinology & Nutrition Service. Hospital de Bellvitge, Spain.

11:15h - 12:45h

LINK BETWEEN DIABETES AND CANCER

Speaker. **Dr. Arkaitz Carracedo**

CIBERONC / CIC bioGUNE, Bizkaia Technology Park / Ikerbasque, Basque Foundation for Science. Bilbao, Spain.

Speaker. **Dra. Ana Belén Crujeiras**

CIBERobn / Laboratory of Molecular and Cellular Endocrinology, Instituto de Investigación Sanitaria, Complejo Hospitalario Universitario de Santiago. Santiago de Compostela, Spain.

12:45h -13:15h

PHARMACOLOGICAL NOVELTIES IN SGLT2-i CLASS

Speaker. **Dr. Richard Carr**

Regional Director Medical Affairs MSD.

13:15h -14:15h

LUNCH

14:15h -15:45h

GLYCAEMIC VARIABILITY, DOES IT MATTER? HOW DO WE MEASURE IT AND ITS CLINICAL IMPLICATION FOR TYPE 2 DIABETES

Speaker. **Dr. Francisco Javier Ampudia**

Endocrinology & Nutrition Service. Hospital Clínico Universitario. Valencia, Spain.

Speaker. **Dra. Virginia Bellido**

Department of Endocrinology. Hospital Universitario Cruces. Barakaldo, Spain.

15:45h -16:00h

WRAP UP

Dr. Eduard Montanya

CIBERDEM Scientific Director, Endocrinology & Nutrition Service. Hospital de Bellvitge, Spain.



Merck Sharp & Dohme de España, S.A. C/ Josefa Valcárcel, 38 · 28027 Madrid. www.msd.es
Copyright © 2019 Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc.,
Kenilworth, NJ, USA. Todos los derechos reservados.
ES-DSM-00133 (Creado: Septiembre 2019)